Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
11 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Genital Diseases, Male"
Show Display Options
Rank Status Study
1 Recruiting Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
Conditions: Recurrent Prostate Carcinoma;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Other: Placebo
2 Recruiting Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate
Condition: Prostate Cancer
Intervention:
3 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
4 Recruiting Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Conditions: Malignant Female Reproductive System Neoplasm;   Malignant Hepatobiliary Neoplasm;   Partner;   Stage III Breast Cancer;   Stage III Cervical Cancer;   Stage III Colorectal Cancer;   Stage III Lung Cancer;   Stage III Prostate Cancer;   Stage III Skin Melanoma;   Stage III Uterine Corpus Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Lung Carcinoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IV Breast Cancer;   Stage IV Cervical Cancer;   Stage IV Colorectal Cancer;   Stage IV Lung Cancer;   Stage IV Prostate Cancer;   Stage IV Skin Melanoma;   Stage IV Uterine Corpus Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colorectal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Cervical Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Behavioral: Cognitive Behavior Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Survey Administration
5 Not yet recruiting Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Biological: Gonadotropin-releasing Hormone Analog;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Radical Prostatectomy
6 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
7 Recruiting Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
8 Recruiting Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castrate Resistant Prostate Cancer
Interventions: Biological: Dendritic Cells DCVAC;   Biological: Placebo;   Drug: Docetaxel;   Drug: Taxotere
9 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
10 Recruiting Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Conditions: Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Renal Pelvis Urothelial Carcinoma;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma;   Stage III Bladder Squamous Cell Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage III Penile Cancer;   Stage III Renal Cell Cancer;   Stage III Renal Pelvis Carcinoma;   Stage III Ureter Cancer;   Stage III Urethral Cancer;   Stage IIIa Penile Cancer;   Stage IIIb Penile Cancer;   Stage IV Bladder Adenocarcinoma;   Stage IV Bladder Squamous Cell Carcinoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Penile Cancer;   Stage IV Renal Cell Cancer;   Stage IV Renal Pelvis Carcinoma;   Stage IV Ureter Cancer;   Stage IV Urethral Cancer;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
11 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment

Study has passed its completion date and status has not been verified in more than two years.